BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
M. William Audeh M.D.	Medical Oncologist Cedars-Sinai Medical Center Associate Clinical Prof. Of Medicine, UCLA
eRA COMMONS USER NAME	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Carleton College, Northfield, MN	BA	06/77	Biology
U. of Minnesota, Minneapolis/St Paul, MN	MS	06/78	Genetics
U. of Iowa, Iowa City, IA	MD	05/82	Medicine
Stanford University Medical Center, Stanford, CA	Intern Resident Chief Resident	07/82-06/86	Internal Mediine
Stanford University Medical Center, Stanford, CA	Fellowship	07/86-06/89	Medical Oncology

A. Personal Statement

I am a medical oncologist specializing in the treatment and prevention of breast cancer. As Medical Director of the Wasserman Breast Cancer Risk Reduction Program, I will help in the design, implementation and analysis of the *STOP Heart Disease in Breast Cancer Survivors* trial. I will work closely with Dr. Armando Giuliano in the recruitment of women into the trial. My current translational projects include:

1. DNA repair inhibition in BRCA-associated cancers. Inhibition of base excision repair (BER) pathway in cell lines deficient in homologous recombination due to homozygous loss of BRCA 1 or 2 function display profound chromosomal abnormalities and cell crisis leading to p53-independent cell death. BRCA mutant cell lines from breast, ovarian and pancreatic tumors all show similar sensitivity, regardless of tissue of origin. BER inhibition is accomplished with small molecule inhibitors of poly(ADP)ribose phosphorylase –1 (PARP1).
2. Detection of homologous repair defects with assay developed by Myriad Genetics – validation, application to predict therapeutic response to alkylating agents and PARP inhibitors.
3. Evaluation of clinical significance of TOX3 in ER+ breast cancer – TOX 3 identified as polymorphic gene affecting risk of breast cancer, also dysregulated in ER+ breast cancer.
4. Role of FOXC1 in biology of triple negative breast cancer
5. Role of PDL-1 in biology of BRCA mutated breast cancers

Breast Cancer clinical trials participation includes:

1. DNA repair inhibitor (PARP inhibition) in patients with breast and ovarian cancer carrying a BRCA mutation: completed and on-going
2. Neoadjuvant therapy of breast cancer with gene expression array analysis to predict response-completed
3. Therapy of metastatic breast cancer with oral VEGFR TKI and aromatase inhibitor-completed
4. PARP inhibitor in metastatic breast cancer with BRCA mutation - 2015
5. Therapy of advanced HER2+ breast cancer with Pertuzumab and herceptin and Taxotere-completed
6. TDM-1 second line therapy in HER2 + metastatic breast cancer – phase II - completed
7. FGFR inhibitron in metastatic breast cancer - 2015
8. Veliparib parp inhibitor with temozolamide in BRCA+ breast cancer – phase III - 2015
9. SWOG Neoadjuvant trial with bevacizumab abd nab-paclitaxel with dose dense AC for LABC and Inflammatory BC-completed
10. Adjuvant vaccine trial with HER2-targeted NeuVax vaccine after adjuvant therapy – 2014-2015
11. Dovitinib FGFR-TKI with Faslodex in metastatic ER+ breast cancer – completed
12. BKM120 (PI3K inhibitor) with faslodex in metastatic ER+ breast cancer – 2015
13. SWOG Adjuvant trial with everolimus in ER+ high risk breast cancer – 2015

14. SWOG Adjuvant chemotherapy trial evaluating anthracycline vs non-anthracycline regimens

Breast Cancer Risk Assessment:
1. Genetic predisposition testing and risk reduction with chemoprevention;
2. Genetic profiling of polymorphic markers in cancer-relevant pathways (xenobiotic metabolism, DNA repair, hormonal metabolism) to determine breast cancer risk;
3. Genetic profiling of polymorphic markers in cancer-relevant pathways (xenobiotic metabolism, DNA repair, hormonal metabolism) to determine modifying effect on BRCA gene penetrance
4. Analysis of polymorphic markers as cofactors in smoking-related breast cancer risk

Co-Investigator for Gilda Radner Program Trials at CSMC
Staff medical Oncologist with GenRisk Medical Genetics Program at CSMC

B. Positions and Honors

C. Selected Peer-Reviewed Publications (in chronological order)

1. Kretschmer, R., Vogel, K., **Audeh, M.W.,** and Gotoff, S. Mechanism of Mouse Resistance to Type 111 Group B Strep. Pathogenic Streptococci M. Parker, Ed. (1979) Reedbooks, Surrey.
2. Kretschmer, R., Vogel, K., **Audeh, M.W.,** and Gotoff, S. Murine Resistance to Type 111 Group B Strep. Infection 2: 54 (1980)
3. Clamon, G., **Audeh, M.W.,** Pinnick, S. Small Cell Lung Carcinoma in the Elderly. J. Am Geriatrics Soc 30: 299-302 (1982)
4. **Audeh, M.W.,** Horning, S.J. Histologic transformation in Non-Hodgkin's Lymphoma: The Stanford Experience including MACOP- B. Blood 70 (suppl 1) : 242a (1987)
5. Strickler, J., **Audeh, M.W.,** Copenhaver, C., and Warnke, R. Immunophenotypic Differences Between Plasmacytoma/Multiple Myeloma and Immunoblastic Lymphoma. Cancer 61: 1782-1786 (1987)
6. **Audeh, M.W.,** Horning, S.J., Brain, S., Hoppe, R.T., Rosenberg, S.A. Results of Prospective Pulmonary Function Testing in the Stanford Hodgkin's Disease Trials. Proc. Am. Soc. Clin. Oncol. 7: 923 (1988)
7. **Audeh, M.W.,** Carlson, R, Jacobs, C, Dunphy, E. Davis, T., and Coleman, N. Long-Term Survival in Advanced Gastric Carcinoma Following Combined Modality Therapy: The Stanford University Experience. Proc. Am. Soc. Clin. Oncol 8: 458 (1989)
8. **Audeh, M.W.,** Carlson, R, Brown W., A Phase II Trial of Carbetimer in Metastatic Colorectal Cancer: A Trial of the Northern California Oncology Group (NCOG). Proc Am. Assoc. Ca. Res. 30: 1019 (1989).
9. **Audeh, M.W.,** Jacobs, C., Davis, Thomas, and Carlson, Robert. A Phase II Trial of Carbetimer for the Treatment of Colorectal Cancer: A Trial of Northern California Oncology Group. American Journal of Clin. Oncol: 13: 324-326 (1990).
10. **Audeh, M.W.,** Jacobs, C. and Rice, D. "Anaplastic Carcinoma, Lymphoma, and , and Miscellaneous Malignancies of the Thyroid and The Role of Chemotherapy" from Thyroid Disease, Stephen A. Falk, Ed. (1990) Raven Press, New York.
11. **Audeh, M.W.,** Memsic L. and Silberman, A. "Anaplastic Carcinoma Lymphoma, Unusual Malignancies and Chemotherapy for Thyroid Cancer" from Thyroid Disease (2nd Edition), Stephen Falk, et al. Raven Press (1997).
12. **Audeh, M.W.,** "Gastrointestinal Cancer and the Cystic Fibrosis Gene" (letter). New England Journal of Medicine: 333:129-130 (1995).
13. **Audeh, M.W.,** "Genetic Predisposition Testing for Breast Cancer" (letter). Cancer J Sci Am 3:254-255 (1997).

14. **Audeh, M.W.,** " MDS and Secondary AML : An Evolutionary Perspective" from Myelodysplastic Syndromes and Secondary Acute Leukemia: Directions for the New Millenium, Raza, A. and Mundle, S., Editors (2001) Kluwer, Boston

15. **Audeh, M. W.,** "Commentary: Management of women at high risk for the development of Breast Cancer" from Surgical Oncology: Multidisciplinary Approach to Difficult Problems, Silberman and Silberman, Editors (2002) Arnold Publishing (Oxford University Press), New York

16. **Audeh, W.,** "Genetic Predisposition to Cancer – Malfunction or Maladaptation?" Horizons in Cancer Therapeutics –From Bench to Bedside 4:3-18(2003) Meniscus Limited, W Conshocken, PA and www.meniscus.com/horizon

17. **Audeh,** M William, "The adoption of gefitinib by the US healthcare system" Signal 4: 10-14 (2003)

18. **Audeh, M. William;** "Genetic and Environmental Factors in Cancer Pathogenesis" from Principles and Practice of Surgical Oncology 2nd Edition, Silberman and Silberman, Editors (2009) Lippincott, William and Wilkins, Philadelphia

19. Tutt, A., Robson, M., Garber, J., Domchek, S., **Audeh, M.W.,** et al. "Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer" J Clin Oncol 27:18s, 2009 (suppl; abstr CRA501)

20. **Audeh, M. William,** Penson, R., Friedlander, M., Powell, B., et al. " Phase II trial of the oral PARP inhibitor olaparib (AZD 2281) in BRCA-deficient advanced ovarian cancer". J Clin Oncol 27:15s, 2009 (suppl; abstr 5500)

21. **Audeh, M.W.,** Carmichael, J., Penson, R., Friedlander, M., et al Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-251 (2010)

22. Tutt, A., Robson, M., Garber, J., Domchek, S., , **Audeh**, **MW.,** et al Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244 (2010)

23. Domchek, S, Mitchell, G, Lindeman, G, Tung, NM…,**Audeh, MW**., et al Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. J Clin Oncol 29:4224-4226 (2011)

24. Hyams, D., de Oliviera, C., Snyder, R., Klein, P., Vinholes, J., **Audeh, M., ...** Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study Cancer Research February 10, 2010 69:204; doi:10.1158/0008-5472.SABCS-09-204

25. **Audeh, M. William**, "Genetic and Environmental Factors in Carcinogenesis" Chapter 2, from Surgical Oncology: Multidisciplinary Approach to Difficult Problems, Silberman and Silberman, Editors (2010) Lippencott Publishing, NY

26. Dang, Catherine, and **Audeh, M.** Chapter 15: "Breast Cancer and Related Diseases", in Gynecologic Oncology: Clinical Practice and Surgical Atlas, Karlan, Li and Bristow, Editors (2012*)* McGraw-Hill New York

27. **Audeh, M. William**. Novel Treatment Strategies in Triple Negative Breast Cancer: The role of PARP inhibitors. Pharmacogenomics and Personalized Medicine 7: 307-316. (2014)

28. Kaufman, B., Shapira-Frommer, R., Schmutzler, RK, **Audeh, MW**…et al Olaparib monotherapy in patients with advanced cancer and a germline BRCA1 or 2 mutation. Journal of Clinical Oncology (2015) 3: 244-250

D. Research Support

No NIH/NCI funding.

Philanthropic gift for Translational Breast Cancer Program: Internal funding of projects under my direction.